At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Morning Light Treatment at Home to Reduce PTSD Symptoms
In Brief
A clinical study evaluating Retimer and Retimer placebo for PTSD. Completed, enrolled 15 participants across 1 site.
Detailed Summary
There is evidence that some of the circadian photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), project directly to the amygdala, an area of the brain implicated in PTSD. Thus, a self-administered morning light treatment at home (shifts clock earlier and stimulates ipRGCs) may be a potentially efficacious adjunctive strategy for reducing PTSD symptoms. This study will test a 4 week daily 1 hour morning light treatment (active vs placebo) in individuals with PTSD. Outcome measures include measures of PTSD and depression.
Study Details
Timeline
Interventions
The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.